Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.

NCT Number	NCT06879704
Lead Sponsor	Centre Henri Becquerel
Conditions	Triple Negative Breast Cancer
Enrollment	115 participants
Start Date	2025-05-28
Primary Completion	2028-02-28 (estimated)
Study Completion	2029-11-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-02